Vitamin D: Effects & State of Evidence — what’s proven and what isn’t

Introduction

Vitamin D is often discussed like a “cure-all”—but scientifically, a clean framing is that it primarily concerns status and supply. The key question is whether a deficiency is present, what baseline values people start with, and what specific end goal is measured (e.g., reversal of rickets, preterm infant outcomes, disease risk). These choices determine whether meta-analyses detect an effect at all.

In the following, I organize the evidence along the practical questions: what is plausible and supported, what remains provisional, and why lifestyle (sunlight, nutrition, exercise) should not be replaced by supplements.

What the effect depends on: status, dose, baseline risk

The evidence base is less “vitamin D works against X” and more: vitamin D supplementation tends to show effects when baseline status is low, and when endpoints match directly (e.g., rickets). Many meta-analyses therefore separate deficiency populations, dosing strategies, and measured clinical targets.

In practice, you need to separate two levels:

1) Status instead of a general effect Many results can be explained because people with vitamin D deficiency start from a different biological and clinical baseline. That increases the chance that supplementation visibly changes something. This is especially relevant when studies do not look at general populations, but at affected risk groups.

2) Dose and strategy questions Meta-analyses often do not examine only “vitamin D vs placebo,” but also low vs high dose regimens or different timing approaches. A good example is the rickets topic: Kaur et al. compare low dose vs high dose in a systematic review and meta-analysis (Kaur et al., 2026, PMID 41701309). Here, “which dose” is clinically central because the probability of achieving the outcome depends strongly on whether the therapy is actually effective enough to address the deficiency or disorder.

3) Outcome determines the conclusion Even if vitamin D is biologically involved, it does not automatically follow that every desired end goal will measurably improve. Your list includes examples with very different target outcomes:

• Body composition in older adults (Matsuyama et al., 2026, PMID 41319491)
• Telomere length as a marker of biological aging (Shen et al., 2026, PMID 41650046)
• Diabetic retinopathy as a microvascular endpoint (Yu et al., 2026, PMID 41454443)

4) Prevalence vs intervention Another “lever” for interpretation: some meta-analyses primarily answer supply and frequency questions (how often deficiency occurs), while others assess effects of supplementation. Cristófalo et al., for example, focus on prevalence in pregnancy (Cristófalo et al., 2026, PMID 40973701). This is relevant for healthcare needs, but not automatically direct proof of causal benefit for all outcomes.

If you keep this in mind, you can interpret study results much better—rather than misreading them generically as a “vitamin D effect.” For readers who want to dig deeper into the comparison between “observational vs intervention,” the article Meta-analyses: effects & state of evidence—what is really proven? provides additional context.

Lifestyle instead of a pill: sun, nutrition, exercise as the baseline

Vitamin D as a supplement is usually most reasonable when you address a deficiency—not as a substitute for core lifestyle habits. The evidence in your list mainly suggests that deficiency is common in certain groups (e.g., pregnancy or knee osteoarthritis). That makes lifestyle and healthcare-system approaches the baseline.

Why prioritize lifestyle over supplements?

1) You change status directly Sunlight and diet genuinely influence vitamin D status. Supplements can complement or correct it, but they do not automatically “bridge” missing exposure or unfavorable dietary patterns—especially when no measured value/clear need exists.

2) Prevalence data show supply problems Several meta-analyses in your list indicate that deficiency is not rare.

• In knee osteoarthritis, the global prevalence of vitamin D deficiency is a highly relevant target in a systematic review and meta-analysis (Iqhrammullah et al., 2026, PMID 40842280).
• In pregnant people, Cristófalo et al. aggregate prevalence data across studies (Cristófalo et al., 2026, PMID 40973701).

Such data strongly argue for first asking: what is the supply situation, how common is deficiency, and which groups are most affected? That is a strategy question—not just the question of a single “pill.”

3) Exercise & body weight act as confounders Behind observed relationships (e.g., metabolism or inflammation) there may be lifestyle factors. In your list, there is an important indirect hint: Huang et al. examine effects of different vitamin D supplements on body fat distribution and glucolipid-related parameters in adiposity-associated metabolic syndrome (Huang et al., 2026, PMID 41731803). Differences reported between products/strategies suggest that “vitamin D” cannot be considered in isolation—diet, activity, and overall metabolic context remain core drivers.

4) Supplements as a targeted add-on If you consider supplements, it should be as a targeted measure: in people at risk, with measurable baseline values, or with a clinical indication. This is especially relevant when making dose decisions (in rickets, the low-vs-high-dose question is clearly outcome-relevant; Kaur et al., 2026, PMID 41701309).

If you want to systematically improve your approach: lifestyle is not “nice to have”; it influences the target variable itself. Supplements are more often the last fine-tuning option—not the main lever.

Evidence hierarchy: meta-analyses vs. observational studies vs. animal data

Your list is dominated by meta-analyses. This increases statistical stability compared with single studies—but it does not automatically mean every meta-analysis proves causal effectiveness. The decisive distinction is whether the evidence evaluates intervention data (supplementation) or only associations (serum levels vs outcomes).

That is how the evidence hierarchy reads in your context:

Meta-analyses (highest evidence density in your selection)

• Intervention-based meta-analyses are closer to causal benefit because they compare supplementation vs control/placebo or compare dose groups.
• Prevalence-based meta-analyses primarily answer: “How common is deficiency?”, not “Does supplementation improve these clinical endpoints?”

Example for intervention closeness:

• Shin et al. pool short- and long-term effects of vitamin D supplementation for preterm infants (Shin et al., 2026, PMID 41057557). Here, the question is immediately clinically relevant: whether supplementation in this population produces measurable effects.

Example for prevalence closeness:

• Cristófalo et al. pool prevalence of vitamin D deficiency in pregnancy (Cristófalo et al., 2026, PMID 40973701).
• Iqhrammullah et al. look at the global prevalence of vitamin D deficiency in knee osteoarthritis patients (Iqhrammullah et al., 2026, PMID 40842280).

Observational/association data (important, but not causal) Associations generate hypotheses, not proof of effectiveness. That’s exactly what you see in your list for:

• Telomere length as a biological aging marker: Shen et al. report a meta-analysis on the association between serum vitamin D levels and leukocyte telomere length (Shen et al., 2026, PMID 41650046). Without intervention confirmation, it remains unclear whether supplementation would causally change this correlation.
• Diabetic retinopathy: Yu et al. report an association between vitamin D deficiency and the risk of diabetic retinopathy (Yu et al., 2026, PMID 41454443). Here too, a clear effectiveness conclusion is typically missing the “appropriate” RCT framing: does supplementation improve the retinal course?

Animal data No animal data are explicitly listed in your set of studies. Therefore, for the specific evaluation of the claims you listed, you should stick strictly to the named meta-analyses.

Practical consequence:

• If you read a meta-analysis on supplementation, you can more reasonably expect potential benefit—though still only for the endpoints and dose ranges that were actually studied.
• If you read a level-outcome association, it is a signal, not treatment proof.

If you want a simple summary of how to order the evidence: intervention studies are the pipeline for decision-making, associations provide clues, and prevalence studies show where healthcare needs are most likely.

What the evidence suggests in practice: disease, population, endpoint

In short: for clear clinical indications (e.g., preterm infants, rickets), the supplementation question is better studied. For other endpoints (biological aging, diabetic retinopathy), meta-analyses often show associations, but evidence for direct effectiveness through supplementation in this form is not automatically present.

Let’s walk through the points in your list by “who/what/result type”:

Knee osteoarthritis: a healthcare problem as an action prompt

Iqhrammullah et al. report in a systematic review and meta-analysis the global prevalence of vitamin D deficiency among knee osteoarthritis patients (Iqhrammullah et al., 2026, PMID 40842280). This does not answer whether supplements clinically improve osteoarthritis—but it provides important healthcare information: if deficiency is common, measuring and addressing it may be more relevant in practice than dosing blindly.

Pregnancy: prevalence and supply needs instead of blanket benefit claims

Cristófalo et al. pool prevalence data for vitamin D deficiency in pregnancy (Cristófalo et al., 2026, PMID 40973701). Again, the core is: how often is deficiency present? This does not yet imply that every supplementation strategy improves every outcome—but it supports the logic of addressing supply gaps systematically.

Preterm infants: supplementation with an eye on short- and long-term effects

Shin et al. examine in a meta-analysis short- and long-term effects of vitamin D supplementation in preterm infants (Shin et al., 2026, PMID 41057557). In your list, this is one of the areas closer to causal questions. Still, which effects occur depends on the endpoints and on the dose/timing regimens studied.

Rickets: dose strategy is central

Kaur et al. compare low dose vs high dose vitamin D in the treatment of nutritional rickets (Kaur et al., 2026, PMID 41701309). This is one of the cleanest practical questions in your list: not only whether vitamin D helps, but how much is plausibly effective within the studied indication.

Adiposity-associated metabolic syndrome: differences by product and strategy

Huang et al. analyze in a meta-analysis effects of different vitamin D supplements on body fat distribution and glucolipid-related parameters in patients with adiposity-associated metabolic syndrome (Huang et al., 2026, PMID 41731803). This suggests that not every “vitamin D” intervention may act the same way—while lifestyle (weight management, movement, nutrition) remains the major driver.

What follows for “diabetes, telomeres, biological aging”?

Yu et al. (diabetic retinopathy; Yu et al., 2026, PMID 41454443) and Shen et al. (telomere length; Shen et al., 2026, PMID 41650046) provide association signals. For practice: this is interesting, but it becomes action-guiding only when appropriate supplementation RCTs directly improve these endpoints (these are not included in your list as primary intervention evidence).

In short: the more directly the endpoint links to vitamin D mechanisms and the more intervention-close the studies are, the stronger the applicability for benefit decisions.

Look closely at “biological aging” and microvascular endpoints

Here, the evidence is more signals than a treatment proof. Meta-analyses frequently show a relationship between vitamin D status and endpoints such as telomere length or diabetic retinopathy—but without intervention results, it remains unclear whether supplementation actually improves disease progression.

Telomere length: association, not automatic causality

Shen et al. pool in a meta-analysis the association between serum vitamin D levels and leukocyte telomere length as a marker of biological aging (Shen et al., 2026, PMID 41650046). Telomere length is a lab/surrogate marker. Even if the relationship is plausible, it does not follow that vitamin D causally slows biological aging or that supplementation measurably improves the same process.

What you should watch for:

• Correlation ≠ causation.
• Telomere length can be influenced by many factors (inflammation, stress, metabolism, lifestyle).
• Without an RCT testing vitamin D against control using telomere length as an endpoint, this remains a hypothesis.

Diabetic retinopathy: clinically relevant, but intervention closeness is missing (in this list)

Yu et al. report in a meta-analysis an association between vitamin D deficiency and the risk of diabetic retinopathy in people with type 2 diabetes (Yu et al., 2026, PMID 41454443). This is clinically relevant because it is a microvascular outcome. But: to make a treatment effectiveness claim, you typically need RCT data or at least intervention studies that directly measure retinopathy progression.

Practical implication for the decision “supplements for diabetes complications?” In your study list, there is no direct, matching RCT or dose-intervention meta-analysis for retinopathy as an outcome. Therefore, vitamin D here should be considered a possible add-on—not a stand-alone strategy. That does not mean “useless”; it means an evidence-critical tradeoff: whether it improves the course in your specific case cannot be justified from association data alone.

When you work with endpoints far from classic deficiency conditions, the core rule is: associations indicate direction, but do not guarantee treatment benefit.

Study overview & interpretation: direction of benefit, evidence strength, open questions

Here is a compact orientation: which of your named studies cover mostly “status/prevalence” and which cover more “intervention/dose”—and where the evidence-based action direction lies.

Direction of benefit: what is “action-relevant”?

• Prevalence says: where there is likely a need (deficiency is common).
• Intervention/dose says: where the chance is larger that supplementation improves endpoints.

Open questions

• For biological aging (telomeres) and diabetic retinopathy, your list is dominated by association logic. Without suitable intervention RCTs, it remains unclear whether vitamin D causally affects these endpoints.
• For “other” outcomes (e.g., body composition), the conclusion depends heavily on the RCT endpoints pooled in Matsuyama et al. (Matsuyama et al., 2026, PMID 41319491).

Interpretation for your next decision

If you want to use vitamin D in a concrete way, the best evidence-based question is: Is deficiency likely or measured? And: Does the target endpoint match the situations/outcomes studied in the available meta-analyses?

What you should take away

• Vitamin D is primarily a “right lever” in deficiency conditions; prevalence meta-analyses show that deficiency is common in relevant groups (e.g., knee osteoarthritis: Iqhrammullah et al., 2026, PMID 40842280; pregnancy: Cristófalo et al., 2026, PMID 40973701).
• The best evidence-based direction comes from intervention/dose meta-analyses (preterm infants: Shin et al., 2026, PMID 41057557; rickets: Kaur et al., 2026, PMID 41701309).
• Associations to “biological aging” or microvascular endpoints are signals, not treatment proofs (telomere length: Shen et al., 2026, PMID 41650046; diabetic retinopathy: Yu et al., 2026, PMID 41454443).
• Lifestyle remains the baseline: sun/nutrition and exercise influence status and many confounders more than any “general” supplement strategy.